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Diabetes is a common cause of kidney failure, and most anti-diabetic agents are excreted
through the kidneys. Therefore, it is critical to adjust medication dosage and anti-diabetic
agents based on kidney function. There are different methods to estimate kidney function,
but the common practice is to use creatinine to estimate the glomerular filtration rate.

(Hossein.akhondiasl@
hcahealthcare.com)

Objective

In this systematic review, we identify and review publications in order to assess differences
between creatinine-based and cystatin C-based estimated glomerular filtration rates in
diabetic patients.

Methods

The articles were identified using 3 databases and were assessed for eligibility. A total of 4
articles were included. Comparisons of the 2 patient groups as well as the patient characteristics were compiled into 2 tables.

Results

Two studies showed significant differences between creatinine-based and cystatin C-based
estimated glomerular filtration rates in patients with type 1 diabetes. There were no significant differences in control or type 2 diabetes groups.

Conclusions

Although cystatin C-based estimation of kidney function looks promising, it fails to show
superiority over creatinine-based estimation. Most studies included in this systematic review, however, had serious limitations to them. Further research with standardized ways of
measuring creatinine and cystatin C is required.
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Introduction

1.1 Diabetes and Hyperglycemia

Diabetes is defined by an impaired homeostasis
in the glucose metabolism resulting in hyperglycemia. In 2014, the International Diabetes
Federation estimated world-wide prevalence
of diabetes to be at 387 million, and in the
year 2035, to be beyond 592 million, of whom
75–85% are classified as type 2 diabetes (T2D).1
The most prevalent types of diabetes are T2D
and type 1 diabetes (T1D). Although rare, there

are several other types of diabetes, including
maturity onset diabetes of the young (MODY)
and late autoimmune diabetes in adults
(LADA).
Prolonged hyperglycemia gives increased risk
for dysfunction in multiple organs as well as
premature death. This risk can be lowered with
the help of anti-diabetic agents (ADA). The
first line of ADA treatment in T2D is metformin. Metformin cannot be metabolized; it
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can only be excreted by glomerular filtration in
the kidneys.2 Other diabetes medications and
antihypertensives are also excreted renally. The
estimation of glomerular filtration rate (eGFR)
is, therefore, pivotal in managing diabetes, as
medications commonly taken for the condition
need careful renal dosing.

1.2 Diabetic Nephropathy and eGFR

Diabetic nephropathy is a term used for kidney
damage caused by diabetes. The progression
of kidney disease is monitored and assessed by
eGFR. A decreasing eGFR indicates declining
kidney function.3 Clinicians routinely use eGFR
to decide appropriate medication and dosage.
The gold standard for measuring GFR is
through a clearance test with iohexol. Iohexol
is a contrast agent that is excreted strictly by glomerular filtration. This exogenous,
tracer-based, clearance test is the method
of choice to accurately calculate GFR. Actual
clearance tests are expensive, impractical, and
demand extra resources, e.g., extra personnel.4 The most common and convenient way
of measuring GFR is by estimating it. Serum
creatinine (crea) and serum cystatin-C (cysc)
are both used for estimation purposes.
Modification of diet in renal disease (MDRD) is
the recommended formula to calculate eGFR
since 2009. MDRD incorporates age and sex
but not muscle mass or diet, 2 factors that
directly affect crea concentrations. eGFR can
also be calculated through the Chronic Kidney
Disease Epidemiology Collaboration (CKDEPI) equation, which incorporates the same
variables as MDRD. The CDK-EPI equation has
less bias, and more appropriately, categorizes
individuals in respect to their long-term clinical
risk and reduces the risk for misclassification
of kidney function.5 In summary, our current
methodologies to estimate GFR have all been
built upon equations that do not account for
the important variables of dietary habits and
body mass, which in most patients, can vary
widely.
While creatinine levels are affected by diet
and body-mass index (BMI), cystatin C is not.6
Cystatin C is an endogenous protein synthesized by all nucleated cells. It is exclusively
excreted via the glomerulus, metabolized and
reabsorbed in the proximal tubule. However,
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there is an individual variation in cystatin C not
related to the kidney function. This variation
is based on how much cystatin C an individual produces, reabsorbs, and eliminates. These
factors can be altered if there is an ongoing
infection, inflammation and various other conditions, e.g., diabetes.7, 8

1.3 Clinical Relevance and Previous
Studies

An estimation of GFR is of absolute importance when treating patients with pharmaceuticals eliminated via the kidneys. If eGFR
overestimates the actual GFR, renally-dosed
medications could potentially lead to intoxication. Whereas, an eGFR that underestimates
the actual GFR might lead to an ineffective
treatment regimen. Sometimes the difference
between eGFR (crea) and eGFR (cysc) is significant without any reasonable explanation. It
is not uncommon that these differences range
over eGFR thresholds for clinical decisions.9 In
a study on 3,418 patients, Stevens et al.10 found
that factors like advanced age, high C-reactive
protein (CRP), high white blood cells and diabetes gave a lower eGFR (cysc) while giving a
higher eGFR (crea) compared to actual measured GFR. The included patients had no other
comorbidities and were selected by previously
known increases in serum creatinine.8, 10 Another study found a significant difference between
eGFR (crea) and eGFR (cysc) in neuro-intensive
and oncological patients compared to cardiology and primary care patients.11 These studies
stress the impact that patient characteristics
can have on eGFR, hence the importance of
unveiling the key mediators affecting creatinine
and cystatin C levels.
The Swedish Agency for Health Technology
Assessment of Social Services (SBU) published
a systematic review over the estimation of
kidney function.12 They found that eGFR (crea)
and eGFR (cysc) were both reliable markers of
measured GFR (mGFR) in most cases. Their
conclusion was that both creatinine and cystatin C should be analyzed when estimating GFR.
They also recommend that in patients with
eGFR < 30 ml/min/1.73 m3, a mean of eGFR
(crea) and eGFR (cysc) should be used. This
recommendation was a consensus after long
discussions between those with divided opinions. The recommendation does not suggest
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that both methods are equivalent; it instead
underlines the importance of further investigations.
An investigation of whether there is a discrepancy between the two major methods of
estimating GFR would therefore have a great
clinical relevance.

Methods

2.1 Objectives

The objective is to review publications that
assessed differences between eGFR (crea) and
eGFR (cysc) in patients with diabetes.

2.2 Search Strategy

The systematic literature search was conducted on three different databases. PubMed (last
searched 2016-10-31), Cochrane (last searched
2016-10-31) and Web of Science Core Collection
(last searched 2016-10-31) were all searched
for relevant studies comparing eGFR (crea) to
eGFR (cysc) in diabetics. The Medical Subject
Headings (MeSH) terms used for this study
were “diabetes,” “glomerular filtration rate,”
“creatinine,” and “cystatin C”.
The detailed strategies for each electronic
search can be found in the appendices: Appendix 1, PubMed; Appendix 2, Cochrane; and
Appendix 3, and the Web of Science Core Collection.

2.3 Inclusion and Exclusion Criteria

Studies that were reviewed were: human studies—publication date from 2011-01-01 to 201610-31 with a sample size greater than 30 in the
diabetic arm, English articles, and studies with
available abstracts. Studies prior to 2011 were
excluded since MDRD was implemented from
that period of time. The sample size limitation
in the diabetic arm was set to greater than 30
in order to increase the power of the included
studies.
Inclusion criteria
• Participants: patients with type 1 or type 2
diabetes
• Intervention: eGFR (crea) and eGFR (cysc)
• Control: a group of non-diabetic people
receiving the same interventions as the
diabetic people
• Outcome: differences in eGFR (crea) and

•

eGFR (cysc) in the intervention group compared to the control group
Study design: clinical and observational
studies

Exclusion criteria
• Non peer-reviewed studies
• Reviews, systematic reviews, meta-analyses, case-control studies or editorial/comment articles
• Studies made on pediatric (<19 years) and
octogenarian population (>79 years), certain indigenous populations (Pima Indians,
etc.) and pregnant women
• Estimation of GFR calculated with
methods other than with creatinine and
cystatin C

2.4 Study Selection

The articles remaining after the initial search
and screening were pooled in a reference manager program (Zotero). Further, the titles were
screened, and any duplicates were removed.
The abstracts were assessed for eligibility and
excluded if not fitting the inclusion criteria. Full
texts of the remaining articles were reviewed.
Due to the nature of systematic reviews no
ethical approvals were needed for the compilation of this study.

2.5 Data Extraction

The study identification, data extraction, data
analyses and result reporting were all executed
in accordance with Preferred Reporting Items
for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines.13 The process of extracting data and reviewing titles, abstracts and full
texts were all independently handled by the
author.
The extraction of data involved study characteristics (author, publication date, design,
methods, number of participants in each arm,
interventions and outcome), patient characteristics (sex-ratio, mean age, mean BMI, comorbidities and medications) and outcome (mean
eGFR (crea) and mean eGFR (cysc)).

2.6 Quality and Risk of Bias
Assessment

The risk of bias in the included studies was
assessed according to the GRADE approach.14
Both Newcastle-Ottawa Scale for quality as-
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sessment (NOS)15 and Cochrane Collaboration’s
tool (CCT)16 are included in the GRADE method. Furthermore, the initial evidence grade
for each study was derived using the same
GRADE approach. For observational studies,
the risk of bias was assessed using NOS. In
this star-based scale, three domains (selection,
comparability and outcome) were assessed
for biases.15 CCT was used for randomized
controlled studies. CCT works by evaluating 7
domains (random sequence generation, allocation concealment, blinding of participants and
personnel, blinding of outcome assessment,
incomplete outcome data, selective reporting
and other biases) for their risks of biases.16

Results

Both the initial evidence grades and the risk of
bias assessment help to evaluate the final quality of evidence of the studies.

A total of 1830 participants were included in
the four studies. The participant composition
was non-diabetic people (n=713), T1D or T2D
(n=709), with the remaining having other types
of diabetes. Despite differences in the objectives, all the studies included a comparison
of eGFR (crea) and eGFR (cysc) in different
groups of diabetics.

2.7 Data Synthesis

All of the extracted data were presented in
either figure or table formats. The study design
and assessment of study quality were derived
using protocols13 and assessment scales14-16 and
are demonstrated in the study characteristic
section of this review.
Papers from PubMed
(n=302)

3.1 Search Results

The search revealed 698 papers from PubMed
(MEDLINE), Web of Science Core Collection,
and Cochrane databases. Most studies (n=295)
were excluded due to their publication date. After the adaptation of limitations and removal of
duplicates, there were a total of 213 papers left
for the eligibility screening. Other limitations
were also considered, and the articles further
eliminated. At the end, there were 4 compatible studies that were analyzed in a systematic
review. (Figure 1)

3.2 Included Studies and Outcome

The study by Natalia Nowak et al. (Study 1)17
evaluated cystatin C as a candidate biomarker
for HNF1A-MODY (a specific genetic subtype

Papers from Web of Science
(n=368)

Papers from Cochrane
(n=28)

Total papers (n=698)
Excluded papers after adapting
limitations (n=390)

Duplicates removed (n=95)

Titles and abstracts
screened for eligibility
(n=213)

• Non-English studies (n=26)
• Publication date < 2012 (n=295)
• Non-human studies (n=51)
• Sample size < 30 (n=11)
• No abstract available (n=7)

Excluded papers (n=180)

Full text articles screened
for eligibility (n=33)

• Due to exclusion criteria (n=77)
• Did not meet inclusion criteria (n=103)

Excluded papers (n=29)

Included articles (n=4)

• Due to exclusion criteria (n=9)
• Did not meet inclusion criteria (n=203)

Figure 1. Flow chart with a full description of the different steps of study selection process.

234

Acaralp and Akhondi. (2020) 1:4. https://doi.org/10.36518/2689-0216.1034

of MODY). This retrospective study included
891 participants with HNFA1-MODY (n=268),
T1D (n=114), T2D (n=244), GCK-MODY (n=170),
HNF4A-MODY (n=39), HNF1B-MODY (n=17),
and non-diabetic people (n=43). For the non-diabetic group and T2D, the difference between
eGFR (crea) and eGFR (cysc) was insignificant.
The same difference for T1D was significant
with a value of 12.5 ml/min/1.73m3.
Magdalena Szopa et al. (Study 2)18 also compared eGFR measured with creatinine and cystatin C in HNF1A-MODY amongst other types
of diabetes. The same intervention comparing
eGFR (crea) and eGFR (cysc) was assessed in
332 participants, made up of HNF1A-MODY
(n=72), GCK-MODY (n=72), T1D (n=53), T2D
(n=70) and non-diabetic people (n=65). The
non-diabetic control group showed a significant difference of -16.9 ml/min/1.73m3 in mean
eGFR. The T1D group also showed a significant
difference of 11.6 ml/min/1.73m3 whereas for
T2D there was no significant difference.
Peter Bjornstad et al. (Study 3)19 measured
GFR through the CKD-EPI formula in a prospective observational study. 1014 people were
included and had either T1D (n=449) or were
assigned to the non-diabetic control group (n=
565). The participants were followed over a
6-year period in order to investigate whether
insulin sensitivity could predict diabetic nephropathy. Baseline data (V1) suggests that
the difference between eGFR (crea) and eGFR
(cysc) for the non-diabetic control group was
-6 ml/min/1.73m3. Whereas, in the T1D group,
the same difference was -3 ml/min/1.73m3.
Follow-up data (V3) suggest the difference in
eGFR for the non-diabetic group increased -3.5
ml/min/1.73m3 to -9.5 ml/min/1.73m3. The difference for T1D increased to -4.1 ml/min/1.73m3.
No statistical testing was done in this study.
Factors associated with overestimating GFR
were assessed in the study by Akihiro Tsuda
et al. (Study 4).20 The study measured eGFR
(crea), eGFR (cysc) and inulin-clearance in 80
participants (40 non-diabetic controls and 40
diabetic people). The difference in eGFR in the
control group was -6.8 ml/min/1.73m3, while
the difference in the diabetic group was -5.6
ml/min/1.73m3. No statistical testing regarding
differences in eGFR (crea) compared to eGFR
(cysc) exists for this study.

3.3 Risk of Bias Assessment

The first study is an observational study17 that
has several crucial selection limitations. The
representativeness of the different cohorts
included in the study cannot, therefore, be determined. Hence, the selection bias may affect
the outcome of the study.
The second observational study18 has an initial
evidence type of 3. It has a few limitations in
both the selection and outcome processes, but
these limitations are interpreted as unlikely to
affect the outcome of interest. Therefore, the
limitations of this study are not as serious as
the first study.
The third study is a prospective observational study19 with an initial evidence type of 2. It
has serious limitations in the selection process
since there are no descriptions for the ascertainment of exposure. This study possesses a
high risk for selection bias because of the lack
of explicit criteria for the selection of participants in the diabetic arm.
The final study is a randomized controlled
study20 with an initial evidence grade of 1. It has
serious limitations due to insufficient generation of random sequence, selective reporting
and other types of biases (e.g., strictly Japanese participants).
Details about the risk of bias assessment for
each study are listed under study characteristics.

Discussion

Previous studies regarding the predictive values
of eGFR, when calculated with creatinine compared to cystatin C in patients with diabetes,
have not been conclusive.21, 22 There are several
factors that affect creatinine concentration in
serum, including age, muscle mass, and diet,
while smoking, BMI, hyperglycemia, and inflammation can affect cystatin C levels.8 Finding
a more reliable method of estimating GFR is
therefore of importance as multiple factors
clearly affects the level of creatinine and cystatin C. A more reliable eGFR value would mean
better medicated patients, lowered risk for
side-effects from medication, earlier detection
of patients with risk for chronic kidney failure
and more accurate detection of dialysis candidates.23, 24
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Previous studies by Tsuda et al. and Eisner et
al. suggest that creatinine and cystatin C easily
overestimate GFR in patients with diabetes.20,25
In order to accurately estimate GFR, we need
to address the main factors affecting the
secretion, excretion, metabolism and reabsorption of creatinine and cystatin C.
In the study by Tsuda et al. (Study 4),20 we
observe higher eGFR (crea) and eGFR (cysc)
in the diabetic group compared to the control
group. The author attributes this overestimation to poor glycemic control. As Tsuda et al.
and Eisner et al. mention in their studies, it is
hypothesized that sustained elevated glucose
levels might lead to increased eGFR in people
with diabetes.20, 25 A suggestion like this would
mean that eGFR would have to be adjusted for this patient group. For creatinine, this
overestimation is explained and attributed to
an increased secretion from renal tubule via
hyperglycemia-induced upregulation of organic
cation transporters. For cystatin C, it is explained as reduced metabolism and reabsorption of the substance in the proximal tubule.20
However, the study has several limitations. It
is a study performed on 80 Japanese participants. Besides the small sample size, the study
also has an ethnic homogeneity that is hard to
generalize on a larger and more diverse cohort.
Also, as seen in the results for patient characteristics, the cohort is composed exclusively of
CKD patients. All of these factors, combined
with an insignificant difference between eGFR
(crea) and eGFR (cysc) in both the diabetic and
control group, make it hard to draw any reliable
conclusions regarding the superiority of one
eGFR-equation over the other.
A very simple and fundamental bias is not
addressed by the author. The study does not
bring up the fact that eGFR-equations are very
dependent on the measured GFR. This means
that eGFR is overestimated when mGFR is low
and underestimated when mGFR is high.26, 27
There are also laboratory differences in eGFR
and mGFR, which are very difficult to assess.
Since inulin and glucose are relatively similar in
structure, the colorimetric detection of inulin
for measurement of GFR is at risk for interference.28 Therefore, poor glycemic control would
automatically lead to falsely elevated inulin
levels and also a false low clearance.
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Other parameters associated with glycemic
control are the level of hemoglobin A1c (HbA1c)
as well as insulin sensitivity. In the study of
Bjornstad et al. (Study 3),19 both parameters
show an association with declining eGFR. The
association is strongest when it comes to rapid
declines of eGFR in T1D patients. Interestingly,
cystatin C detects rapid eGFR decline more
accurately than creatinine in T1D, which may be
of clinical importance when assessing conditions like acute kidney failure. eGFR (cysc) also
shows a greater association with insulin sensitivity index (ISI) than eGFR (crea).19 Hence, the
study author insinuates that cystatin C-based
equations might be superior to those of creatinine when it comes to monitoring diabetic
nephropathy. However, further research is
required in order to establish the superiority of
cystatin C in patients with diabetes. The concentration of cystatin C varies and is affected
by the degree of inflammation, cardiovascular
disease and insulin sensitivity. The advantage of
cystatin C is that it is an entirely glomerular-filtered endogenous substance that reacts fast
to early signs of diabetes like microalbuminuria.
(Table 1)
However, there are some limitations to the
study done by Bjornstad et al.19 as well. The first
limitation is that there are no direct measurements of GFR with either inulin or iohexol.
Another limitation is the fact that there are no
real measurements of insulin sensitivity. Instead the author chooses to estimate the sensitivity and calculate ISI through an equation
based on waist circumference, body weight,
daily insulin dose, triglyceride levels and diastolic blood pressure. There are many ways of
overcoming this limitation, including acknowledged indices that estimate insulin sensitivity
as well as the insulin glucose clamp, which is
the gold standard for quantifying insulin sensitivity.29 A third limitation regards the selection
bias in this study. Some participants with T1D
were excluded because of incomplete data at
baseline. These participants reportedly also had
worse renal function and lipid panel, meaning
that the study group was not reflecting the
initial T1D group or T1D patients in general.19
There seems, however, to be a clear linkage between glycemic control, insulin sensitivity, and
eGFR as shown in this study as well as previous
studies.19,20,30 Due to the serious limitations of
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Table 1. Patient Demographics by Group Including Age, Sex and Charlson Comorbidity Index

Natalia Nowak
et al. 2013

Magdalena
Szopa et al.
2015

Peter
Bjornstad et
al. 2013

Akihiro Tsuda
et al. 2014

Groups

Mean age

Sex ratio Mean BMI
(F N (%))

Comorbidities

Medication

Control (n=43)

32.3 ± 3.95

26 (60.5)

23.6 ± 1.35

No known.

No known.

T1D (n=58)

36.1 ± 3.05

37 (66.1)

23.6 ± 1.05

CKD (n=5)

No known.

T2D (n=41)

57.9 ± 2.8

25 (61.0)

33.9 ± 2.4

CKD (n=5)

No known.

Control (n=65)

38.02 ± 11.70

23 (35.4)

23.91 ± 2.93

T1D (n=53)

31.72 ± 11.71

21 (55.7)

24.43 ± 3.20

T2D (n=70)

58.96 ± 10.25

39 (55.7)

30.48 ± 4.76

Exclusion of participants with thyroid
problems, infections,
neoplasms, chronic
respiratory disease,
kidney and liver
disease

Exclusion of
participants on
steroid therapy.

Control V1
(n=565)

40.2 ± 8.8

277 (49)

26.0 ± 4.8

Hypertension (n=16)

ACEi/ARB (n=3)
Statins (n=7)

T1D V1 (n=449)

36.7 ± 8.7

238 (53)

26.1 ± 4.3

Hypertension (n=39)

ACEi/ARB
(n=32)
Statins (n=16)

Control V3
(n=565)

46.8 ± 8.8

283 (50)

26.5 ± 4.9

Hypertension (n=24)

ACEi/ARB (n=8)
Statins (n=19)

T1D V3
(n=449)

43.3 ± 8.7

243 (54)

26.7 ± 4.6

Hypertension (n=54)

ACEi/ARB
(n=46)
Statins (n=47)

Control
(n=40)

48.3 ± 15.8

21 (52.5)

24.3 ± 4.7

Restricted to participants with chronic
kidney disease
(CKD).

Diabetic group
(n=40)

64.8 ± 9.5

24 (60.0)

25.4 ± 3.4

Exclusion of participants with thyroid
problems.

Exclusion of
participants
with medication
that may alter
tubular creatinine secretion.

this study (e.g., no mGFR), it is hard to agree
that eGFR (cysc) is superior to eGFR (crea).
(Table 2)
In order to answer the question of whether
eGFR (crea) or eGFR (cysc) is the superior
estimate in people with diabetes, we also need
to discuss the results of the studies by Nowak
et al. (Study 1)17 and Szopa et al. (Study 2).18
In both studies, eGFR (crea) was significantly
higher than eGFR (cysc) in patients with T1D.
No significant differences were measured for
T2D. Furthermore, adjustments for confounders like gender, age, BMI, glucose level, CRP
concentration, HDL level and total cholesterol
level did not alter the observed differences in
the studies, which implies that the observed
difference in eGFR is independent from the
aforementioned factors. The difference between eGFR (crea) and eGFR (cysc) can, therefore, not be attributed to muscle mass, degree
of inflammation or glycemic control. Interestingly, previous studies have shown that cystatin

C is more effective at detecting mild diabetic
nephropathy and that this superiority over
creatinine-based equations is evened out at
GFR values below 60 mL/min.31, 32 The significant
discrepancy observed between eGFR (crea) and
eGFR (cysc) in T1D patients in the studies by
Nowak et al.17 and Szopa et al.18 could then be
a result of the superior cystatin C estimation.
On the other hand, there was no significant
difference between eGFR values in patients
with T2D, which would indicate that cystatin C
superiority in mild diabetic nephropathy probably is not the explanation for the significant
difference seen in the T1D group.
Both of the studies fall short because of the
fact that there were no actual mGFR assessments. Some other limitations to these studies are the relatively small sample sizes and
the fact that T1D and T2D groups differed in
some clinical features. Since both studies are
done on different cohorts and show the same
results, it may be tempting to jump to con237
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Table 2. Primary outcome measures comparing eGFR (crea) with eGFR (cysc) in healthy and diabetic populations. All values are given in the unit of ml/min/1.73m3 as a measure of eGFR.

Natalia Nowak et al. 2013

Magdalena Szopa et
al. 2015

Peter Bjornstad et al.
2013

Akihiro Tsuda et al.
2014

Control (n=43)

T1D (n=56)

T2D (n=41)

Mean eGFR (crea)
111.9 ± 4.75

Mean eGFR (crea)
101.2 ± 6.00

Mean eGFR (crea)
82.4 ± 7.10

Mean eGFR (cysc)
113.3 ± 5.80

Mean eGFR (cysc)
88.7 ± 1.30

Mean eGFR (cysc)
79.5 ± 7.85

Difference in eGFR
-1.4

Difference in eGFR
12.5

Difference in eGFR
2.9

Control (n=65)

T1D (n=53)

T2D (n=70)

Mean eGFR (crea)
99.5 ± 14.35

Mean eGFR (crea)
111.5 ± 15.8

Mean eGFR (crea)
88.7 ± 16.99

Mean eGFR (cysc)
116.2 ± 15.5

Mean eGFR (cysc)
100.0 ± 17.55

Mean eGFR (cysc)
89.6 ± 21.64

Difference in eGFR
-16.7

Difference in eGFR
11.5

Difference in eGFR
-0.9

Control V1 (n=565)

T1D V1 (n=449)

Control V3
(n=565)

T1D V3 (n=449)

Mean eGFR (crea)
102 ± 20

Mean eGFR (crea)
105 ± 24

Mean eGFR (crea)
96.5 ± 14.5

Mean eGFR (crea)
106 ± 21.4

Mean eGFR (cysc)
108 ± 12

Mean eGFR (cysc)
108 ± 18

Mean eGFR (cysc)
106 ± 14.0

Mean eGFR (cysc)
102 ± 22

Difference in eGFR
-6

Difference in eGFR
-3

Difference in eGFR
-9.5

Difference in eGFR
4

Control (n=40)

Diabetic group
(n=40)

Mean eGFR (crea)
53.2 ± 22.0

Mean eGFR (crea)
75 ± 20.2

Mean eGFR (cysc)
60 ± 29.6

Mean eGFR (cysc)
80.6 ± 22.4

Difference in eGFR
-6.8

Difference in eGFR
-5.6

clusions. The studies should instead be taken
cautiously due to their serious limitations.

4.1 Strengths and Limitations

Our study is a systematic review covering a
field of medicine that is somewhat divided in
research and opinions. We believe we have a
high level of evidence and a potential recommendation for use of eGFR (cysc) over eGFR
(Crea), specifically in T1D.
This systematic review should, however, be
interpreted within its limitations. First and
foremost, the quality assessments of the
studies were only based on their risk of bias
and initial evidence type. To determine the final
evidence, a more complete quality assessment
is required. Moreover, no statistical tests were
performed in this study. When comparing two
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interventions, statistical analysis, hence a meta-analysis, is of great value.
Mapping and investigating non-renal factors
affecting cystatin C is essential for the clinical
applicability of eGFR (cysc). The analysis method for cystatin C needs to be standardized
between clinical settings and new reference intervals for patients with and without diabetes
needs to be established. Furthermore, there
is a need to show that eGFR (cysc) compared
to eGFR (crea) improves the risk stratification
for nephropathy. Until then, creatinine-based
eGFR will remain the most clinically applicable
method for the estimation of GFR.

4.2 Future Research

There are still some ambiguities and uncertainty regarding non-renal factors that regulate

Acaralp and Akhondi. (2020) 1:4. https://doi.org/10.36518/2689-0216.1034

creatinine and cystatin C levels. Therefore, the
production, secretion, metabolism and reabsorption of these compounds need further investigation. Larger cohort sizes, adequate mGFR
methods, standardized ways of measuring serum
creatinine, and cystatin C, as well as urinary creatinine and cystatin C, needs to be adapted when
conducting future studies.

Conclusion

Although cystatin C-based GFR equations look
promising, they fail to show superiority over creatinine-based equations in this study. However,
due to the serious limitations of the included articles, there is a need for further research in order
to be certain of such a conclusion.
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Study Characteristics
Study 1: Natalia Nowak et al. 2012
Title: Cystatin C is not a good candidate biomarker for HNF1A-MODY

Study Design
Type

Retrospective comparative study
Cross-sectional study
Observational study

Participants

891 patients from three different centers
HNFA1-MODY (n=268), T1DM (n=114), T2DM (n=244), GCK (n=170), HNF4A
(n=39), HNF1B (n=17) and non-diabetic control (n=43)

Interventions

Comparison of eGFR CDK-EPI (crea) vs. MDRD eGFR (cysc)

Outcomes

In patients with HNF1A-MODY, cystatin C-based eGFR is higher than creatinine-based one. The study suggests that cystatin C may not be a good
biomarker for HNF1A-MODY since the low CRP levels associated with HNF1A-MODY can affect cystatin C levels, thus overestimating GFR compared to
creatinine-based equations.

Limitations

The intergroup difference seen in samples from the Polish center is not found
in samples from the remaining centers in the UK. Different cystatin C assays
or differences in recruitment procedures may be the cause. The study also uses
different equations for calculation of eGFR (crea) and eGFR (cysc).

Assessment of the Quality of Evidence
Evidence type

3 (retrospective comparative study)

Risk of bias

Very serious limitations (-2)
Selection:
-The representativeness of the exposed cohort cannot be determined since
there is no description of the derivation of the cohort.
-There is no description of the derivation of the non-exposed cohort.
-There is no description regarding the ascertainment of exposure.
-There are no demonstrations that the outcome of interest was not present
at start of the study.
Comparability:
-The study controls for differences in eGFR (crea) and eGFR (cysc). *
-The study controls for additional factors including sex-ratio, mean age and
mean BMI. *
Outcome:
-There is a record linkage for the assessment of outcome (measurements,
e.g., eGFR, BMI). *
-The follow up was long enough for outcomes to occur. There was no follow-up but for the outcome of interest there is none needed. *
-There is no statement of the adequacy of follow up of cohorts.
Selection (0/4 stars). Comparability (2/2 stars). Outcome (2/3 stars).

240

Acaralp and Akhondi. (2020) 1:4. https://doi.org/10.36518/2689-0216.1034

Study 2: Magdalena Spoza et al. 2015
Title: Comparison of Glomerular Filtration Rate Estimation from Serum Creatinine and Cystatin
C in HNF1A-MODY and Other Types of Diabetes

Study Design
Type

Retrospective comparative study
Cross-sectional study
Observational study

Participants

332 participants from one center
HNF1A-MODY (n=72), GCK-MODY (n=72), T1DM (n=53), T2DM (n=70) and
non-diabetic control (n=65)

Interventions

Comparison of eGFR CDK-EPI (crea) vs eGFR CDK-EPI (cysc)

Outcomes

eGFR (cysc) has shown to be less biased in diabetes with poor glycemic control. Interestingly, for T1DM-patients in this study, eGFR (crea) is significantly
higher than eGFR (cysc). The authors suggest that creatinine-based equations
under euglycemic conditions can overestimate the inulin-based assessed GFR;
whereas, under hyperglycemic conditions it can underestimate GFR.

Limitations

There is no reliable gold standard for measuring GFR (inulin or iothalamate).
The study has a small sample size. The study group differs in terms of some
clinical characteristics. The participants included have an eGFR of 60 ml/
min/1.73 m or above, which means participants with advanced stage of renal
disease were excluded.

Assessment of the Quality of Evidence
Evidence type

3 (retrospective comparative study)

Risk of bias

Serious limitations (-1)
Selection:
-The exposed cohort is somewhat representative of the average T1D and T2D
people in the community. *
-The non-exposed cohort is drawn from the same community as the exposed
cohort (white Caucasians residing in southeastern Poland).*
-There is a clear ascertainment of exposure for both exposed cohort and control cohort (clinical symptoms and fasting blood glucose levels). *
-There are no demonstrations that outcome of interest was not present at
start of the study.
Comparability:
-The study controls for differences in eGFR (crea) and eGFR (cysc). *
-The study controls for additional factors including sex-ratio, mean age, mean
BMI, comorbidities and medications. *
Outcome:
-There is a record linkage for the assessment of outcome (measurements e.g.
eGFR, BMI). *
-The follow up was long enough for outcomes to occur. There was no follow-up but for the outcome of interest there is none needed. *
-There is no statement of the adequacy of follow up of cohorts.
Selection (3/4 stars). Comparability (2/2 stars). Outcome (2/3 stars).

241

HCA Healthcare Journal of Medicine

Study 3: Peter Bjornstad et al. 2013
Title: Early Diabetic Nephropathy: A complication of reduced insulin sensitivity in type 1 diabetes

Study Design
Type

Prospective comparative study
Cross-sectional study
Observational study

Participants

1014 participants
T1DM (n=449) and non-diabetic controls (n= 565)

Interventions

Comparison of eGFR CDK-EPI (crea) vs. eGFR CDK-EPI (cysc) vs CDK-EPI
(crea-cysc)
Relate eGFR to insulin sensitivity index (ISI)

Outcomes

Rapid GFR decline is associated with worsened ISI. eGFR CDK-EPI (cysc) is
less biased and better at detecting a rapid decline of GFR.

Limitations

There is no direct measurement of GFR or insulin-sensitivity. Some T1DM patients without baseline data have worse renal function and lipid profile, which
may bias the results since less healthy patients were not included.

Assessment of the Quality of Evidence
Evidence type

2 (prospective comparative study)

Risk of bias

Serious limitations (-1)
Selection:
-The exposed cohort is somewhat representative of the average T1D people in
the community. *
-The non-exposed cohort is drawn from the same community as the exposed
cohort (19–56 year olds that were asymptomatic for cardiovascular disease).*
-There is no description regarding the ascertainment of exposure.
-There are no demonstrations that outcome of interest was not present at
start of study.
Comparability:
-The study controls for differences in eGFR (crea) and eGFR (cysc). *
-The study controls for additional factors including sex-ratio, mean age, mean
BMI, comorbidities and medications. *
Outcome:
-There was a record linkage for the assessment of outcome (measurements,
e.g., eGFR, BMI). *
-The follow-up was long enough for outcomes to occur (6 years). *
-There were a small number of participants lost at follow up. The 1–2% loss is
unlikely to introduce bias. *
Selection (2/4 stars). Comparability (2/2 stars). Outcome (3/3 stars).
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Study 4: Akihiro Tsuda et al. 2014
Title: Poor Glycemic Control Is a Major Factor in the Overestimation of Glomerular Filtration
Rate in Diabetic Patients

Study Design
Type

Randomized controlled study

Participants

80 participants
DM (n=40) and non-diabetic controls (n=40)

Interventions

Comparison between inulin clearance vs. eGFR (crea) and eGFR(cysc)

Outcomes

As glycemic control worsens, eGFR overestimates inulin clearance. Comparing inulin clearance agreement with eGFR (crea) and eGFR (cysc) shows
eGFR overestimates the glomerular filtration rate, especially when calculated
through serum-creatinine. Factors associated with overestimation includes
HbA1c and glycolated albumin. It’s suggested that the organic cation transporters responsible for creatinine secretion is modulated by high glucose. A
new formula is suggested where creatinine is corrected for hba1c.

Limitations

The study has a small sample size. The study has only Japanese participants,
which makes the results and the new formula harder to apply to other ethnic
groups. The authors cannot offer an explanation why eGFR (cysc) also overestimates the glomerular filtration rate.

Assessment of the Quality of Evidence
Evidence type

1 (randomized controlled study)

Risk of bias

Serious limitations (-1)
Random Sequence Generation:
-Allocation is based on clinical history or the results of laboratory tests, which
has a high risk of bias.
Allocation Concealment:
-There is insufficient information regarding allocation concealment, creating
an unclear risk of bias.
Blinding of Participants and Personnel:
-No blinding is used, but the outcome is not likely to be influenced by the
absence of blinding, thus a low risk of bias.
Blinding of Outcome Assessment:
-No blinding is used, but the outcome is not likely to be influenced by the
absence of blinding, thus a low risk of bias.
Incomplete Outcome Data:
-No missing outcome data is reported, thus a low risk of bias.
Selective Reporting:
-One or more primary outcomes are reported using measurements, analysis
methods or subsets of the data that were not pre-specified, creating a high
risk of bias.
Other Bias:
-The study has a potential source of bias (n=80 and all Japanese participants)
related to the specific study design used, creating a high risk of bias.
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Appendices
Appendix 1
Search strategy for database: PubMed
Last search: 2016-10-31
Search strategy
1. Diabetes AND glomerular filtration rate AND creatinine AND cystatin c (302 hits)
2. English (287)
3. Date 2012–2016 (160)
4. Human (114)
5. Sample size > 30 (108)
6. No abstract available (105)
Query translation for the initial search: (“diabetes mellitus”[MeSH Terms] OR (“diabetes”[All Fields]
AND “mellitus”[All Fields]) OR “diabetes mellitus”[All Fields] OR “diabetes”[All Fields] OR “diabetes
insipidus”[MeSH Terms] OR (“diabetes”[All Fields] AND “insipidus”[All Fields]) OR “diabetes insipidus”[All Fields]) AND (“glomerular filtration rate”[MeSH Terms] OR (“glomerular”[All Fields] AND
“filtration”[All Fields] AND “rate”[All Fields]) OR “glomerular filtration rate”[All Fields]) AND (“creatinine”[MeSH Terms] OR “creatinine”[All Fields]) AND (“cystatin c”[MeSH Terms] OR “cystatin c”[All
Fields]).

Appendix 2
Search strategy for database: Cochrane
Last search: 2016-10-31
Search strategy
1. Diabetes AND glomerular filtration rate AND creatinine AND cystatin c (28 hits)
2. English (28)
3. Date 2012–2016 (21)
4. Human (21)
5. Sample size > 30 (20)
6. No abstract available (20)

Appendix 3
Search strategy for database: Web of Science Core Collection
Last search: 2016-10-31
Search strategy
1. Diabetes AND glomerular filtration rate AND creatinine AND cystatin c (368 hits)
2. English (357)
3. Date 2012–2016 (196)
4. Human (191)
5. Sample size > 30 (187)
6. No abstract available (183)
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